Pharmaceutical

Opzelura by Incyte for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE): Likelihood of Approval

Opzelura is under clinical development by Incyte and currently in Phase II for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE).

May 17, 2024 - 04:00
Opzelura is under clinical development by Incyte and currently in Phase II for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE).
Read the original article

Tags:

Previous Article

SCDARIC-33 by Regeneron Pharmaceuticals for Refractory Acute Myeloid Leukemia: L...

Next Article

Opzelura by Incyte for Graft Versus Host Disease (GVHD): Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

What explains rare heart condition among young men after Covid vaccines? A new study offers clues

What explains rare heart condition among young men afte...

May 5, 2023

OMERS snaps up drug royalties and milestones from Xencor for $215m

OMERS snaps up drug royalties and milestones from Xenco...

Nov 8, 2023

STAT+: Illumina chief commercial officer leaves to lead liquid biopsy startup Delfi

STAT+: Illumina chief commercial officer leaves to lead...

Jan 4, 2024